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1. Introduction
Uveitis represents a significant burden of visual loss causing around 10–15% of 
all cases of blindness in the United States, and it is the fifth cause of visual loss in 
the developed world, accounting for up to 20% of legal blindness [1]. Visual loss 
due to uveitis currently has a significant impact on the productivity and quality of 
life of many patients worldwide. Therefore, advances in research and development 
of diagnostic techniques and therapeutic strategies are crucial for patients suffering 
from many forms of infectious and autoimmune intraocular inflammation.
One of the main obstacles that ophthalmologists face on diagnosis and treatment 
of eye disease is the unique complexity of the physical and physiological barriers, as 
well as the delicate anatomical structures of the human eye. This biologic scenario, 
particularly in highly destructive tissue disorders like infectious and autoimmune 
uveitis, represents a challenge for early and accurate diagnosis and effective therapy. 
Even today, with all possible diagnostic resources available in tertiary eye care 
facilities, more than 30% of patients suffering from uveitis do not have a definitive 
etiologic diagnosis [2]. The same is true for current therapeutic methods which 
suffer from lack of specificity, and are limited to availability at the site of inflam-
mation due to the complex anatomical and physiological characteristics of the eye 
[3]. Therefore, the development of improved diagnostic methods and therapeutic 
modalities for inflammatory ocular disorders has recently received special and 
intense attention by the uveitis research community.
2. Advances in diagnosis of uveitis
In the past decades, scientific research at the molecular level and technologi-
cal development have revolutionized medicine like never before. Such advances, 
particularly those related to detection technology are significant since early, and 
accurate diagnosis allows prompt and adequate treatment. Molecular biology has 
revolutionized medicine with the promise of improving our understanding of the 
pathogenic mechanisms that produce disease. The human plasma proteome has 
become the primary target for molecular analysis directed to improve the diagnosis 
and monitor the therapeutic response of many systemic and ocular disorders. 
There are at least eight different classes of plasma proteins classified by designed 
and functional basis. Two such groups are: the “tissue leakage products,” which are 
intracellular proteins that are released into the plasma due to cell damage or death; 
and the “foreign proteins,” which come from infectious microorganisms or parasites 
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and are released or exposed to the plasma are the main, but not the only source for 
diagnostic assays. The plasma proteome has been typically analyzed by electro-
phoresis combined with chromatography and mass spectrometry [4]. However, 
many new diagnostic methods have emerged, like DNA microarrays, which may be 
used for disease diagnosis by detecting biomarkers (genotyping, post-translational 
modifications, multi-SNPs marker screening, and determination of disease-rele-
vant genes); detecting infectious agents (bacteria, virus, and fungal detection); and 
genetic disorders (detection of chromosome abnormalities, mutation analysis, and 
screening of SNPs) [5]. This methodology may interact with other molecular detec-
tion methods to study different disease biomarkers from blood, saliva, and other 
body tissues and fluids like aqueous and vitreous humors. For example, the ability 
to measure a wide range of molecular components in saliva and compare them to 
the plasma proteome has become a feasible way to study immunologic markers 
and microbes for autoimmune and infectious diseases, respectively [6]. Another 
application of molecular tools like polymerase chain reaction (PCR) has improved 
the timing for confirmatory diagnosis of infectious uveitis and endophthalmitis [7]. 
However, the number and type of microorganisms that may be studied in a given 
sample is limited due to differences in amplification techniques, as well as primers 
and fluorescent labels availability on multiplex detection systems. More recently, 
the use of next-generation sequencing (NGS) has proven to be a promising diagnos-
tic strategy for multiple detections of common and rare microorganisms, including 
virus associated with infectious uveitis and endophthalmitis present in single vitre-
ous samples. An important contribution of NGS so far is related to the improvement 
of pathogen detection in cases of negative culture endophthalmitis [8].
Despite these promising advances, the development and implementation of 
many new diagnostic techniques still need to be assessed for their effectiveness 
regarding precision and accuracy; sensitivity and specificity; predictive value, 
and cost-benefit balance convenience to be standardized and used widely on a 
clinical basis.
Imaging diagnostic methods have also suffered significant improvement. The 
development of the ocular coherence tomography (OCT) which provides non-
contact, in vivo, cross-sectional, high-speed, and high-resolution images of dif-
ferent ocular structures including the cornea, anterior segment, retina, and optic 
nerve has evolved from low resolution time-domain image acquisition technology, 
to spectral domain and swept-source high-definition OCT with en-face, more 
in-depth, and extended image acquisition modalities [9]. Another significant 
advancement in diagnostic imaging technology is the development of multimodal 
devices, which allow the use of different complementary imaging techniques like 
fluorescein and indocyanine green digital angiography, wide-field angiography, 
autofluorescence, OCT, and OCT-Angiography all-in-one single machine [10]. Such 
multimodal equipment has permitted saving costs, time, office space, and less 
personal rotation when performing multiple studies to a single patient.
Another innovative and very exciting development in ocular image analysis 
has to do with artificial intelligence (AI), a new field of computer science research 
that will dramatically change the diagnostic and therapeutic pathways of many 
chronic degenerative ocular conditions including uveitis. Artificial intelligence 
already permits early identification of diabetic retinopathy, glaucoma, age-related 
macular degeneration, retinopathy of prematurity, refractive errors, and cardio-
vascular risk factors based on color fundus photographs through deep learning 
algorithms [11]. Very soon, patients will routinely be taken a non-mydriatic 
fundus photograph at the pre-exam room by an ophthalmic technician allowing 
the accurate recognition of many systemic associated and primary ocular dis-
orders. Image pattern recognition is the basis of this technology, which requires 
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a large number of fundus photographs to learn from (training dataset) as well 
as a separate database for validation (validation dataset) [12]. This technology 
may be coupled with imaging diagnostic devices, such as a fundus camera with 
fluorescein, indocyanine green, and autofluorescence capabilities; SD-OCT, 
swept soured OCT, OCT-A, corneal topography, visual system aberrometry and 
wavefront imaging, anterior segment tomography, and ultrasound, among others, 
for the detection of specific diagnoses. Soon, this technology will be applied to 
patients with different forms of uveitis with specific and characteristic clinical 
appearance analyzed by different image diagnostic devices that will permit the 
accurate computerized diagnosis in a routine exam.
3. Advances in therapy of uveitis
Topical therapy with eye drops makes up more than 90% of ophthalmic 
formulations including different corticosteroids and non-steroidal anti-inflam-
matory eye drops. However, their intraocular bioavailability is limited by tear 
clearance, nasolacrimal drainage, and limited penetration related to the anterior 
biological barriers including the corneal epithelium and the hemato-aqueous 
barrier. Moreover, protein binding and enzymatic degradation also account for 
the limited absorption into target tissues [13]. Many different drug delivery strat-
egies, including prodrugs, chemical permeability enhancers, stimuli-responsive 
in situ gels, and drug delivery carriers like liposomes are being developed to 
counter the elimination mechanisms mentioned before [14]. The emergence of 
nanotechnology has impulse the development of such therapeutic strategies for 
many ocular diseases including uveitis. Different active drugs have been coupled 
with nanocarriers to overcome the ocular anatomic barriers for direct interaction 
with specific intraocular tissues, increasing their therapeutic efficiency. Drugs 
loaded into nanoparticles improve their pharmacodynamics and pharmacoki-
netics and at the same time, reduce their immunogenicity, biorecognition, and 
toxicity [15]. One of the most developed fields in ophthalmic pharmacology is 
the sustained-release intraocular drug delivery devices. Polymeric-controlled 
release microparticle injections and implants, cyclodextrin-based nanospheres, 
nanocapsules, microencapsulated cells, liposomes, nano-micelles, and den-
drimers are among the most used methods to deliver anti-inflammatory and 
immunomodulatory drugs into the eye [15, 16]. Such strategies are intended to 
avoid the side effects of prolonged systemic corticosteroids and immunosup-
pressive chemotherapy. An intraocular injection may provide a high-dose of 
medication directly into the site of inflammation with few or no systemic side 
effects. However, this therapeutic approach is not exempt from potential serious 
complications like endophthalmitis, vitreous hemorrhage, and retinal detach-
ment, particularly when the administration needs to be repeated several times 
to achieve their purpose [17]. So far, several polymeric implants are already 
being used for the control of intraocular inflammation, including corticosteroid 
formulations [18]. Many other nanotechnology carriers mentioned before may 
be coupled with different drugs like cyclosporine-A, ganciclovir, non-steroidal 
anti-inflammatory drugs, anti-angiogenic, and anti-glaucoma medications to be 
delivered intraocularly. However, because nanoparticles are recently developed, 
they face several challenges including the need for extensive in vivo studies in 
animal models and then in humans to validate their efficacy and safety. Another 
essential task is the identification of specific ocular disease-related biomarkers 
and their cellular and molecular function to develop target-specific drugs that 
block the biomarker function.
Advances in the Diagnosis and Management of Uveitis
4
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
More recently, transscleral iontophoresis has been employed to deliver sufficient 
dose medications into the eye in a non-invasive way, avoiding injections or the 
implantation of sustained-release drug devices with minimal side effects [19].
On the other hand, many specific, target-directed biologic molecules manu-
factured by recombinant DNA technology are used for treating joint systemic 
and ocular autoimmune inflammation. Such molecules consist of monoclonal 
antibodies, soluble receptors, cytokines, natural cytokine antagonists, and acces-
sory molecules in antigen presentation. They play critical roles in the pathogenesis 
of inflammatory uveitis, like TNF-α, IL-1, IL-6; IL-17, T, and B-lymphocytes; and 
adhesion molecules like LFA-1 and ICAM-1 [20].
Future therapeutic strategies that may be exploited include immune tolerance, 
inducers of apoptosis, neuroprotective agents, gene therapy, gene transcription 
factors, and other modulating molecules that permit reprogramming of cells in vivo.
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